Greenleaf Fund
340 W. 42nd Street, Floor 2, New York, NY, 10036, United States
Overview
Green Leaf Investment Fund primary driving force is to find or create the best possible outcome for our investors, strategic partners, capital recipients.They have constantly looking for new ways to improve their offering through market innovation. Technology plays an important role in how we approach every new fund or opportunity.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Financial Services
Investment portfolio
- Canopy Biosciences
Participated · Series A · May 2018
Canopy Biosciences develops and commercializes research tools focused on gene editing and expression analysis. The company was founded in September 2016 and operates out of the BioGenerator Labs in St. Louis, Missouri. Its lead technology is licensed through Washington University in St. Louis and it already serves customers in Europe, India, Japan, and South Korea. Canopy has demonstrated a rapid path to revenue, launching four product lines and two services within the past year. The company plans to use new funding to develop additional research tools, commercialize cutting-edge products, and hire more employees. Canopy was founded by Edward Weinstein, David Smoller, and Crystal Winkeler.
Team
Douglas DiSanti
CEO & President
LinkedIn